High TMB has been defined as >23.1 mutations/Mb in patients with melanoma9; >100 mutations per tumor in patients with melanoma treated with antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4)11; >10 mutations/Mb in patients with non-small cell lung cancer7; and ≥ 20 mutations/Mb in patients with various tumor types treated with immuno-oncology therapy10. Here, CTLA4 is linked to melanoma.